229 completed. 229 Phase 3, 9 Phase 2.
By phase and status
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Trials (filtered) newest first · largest first
All 229 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
fenfluramine - Dravet Syndrome | Phase 3 | Completed | 25 | 2024-05-21 | 2026-09-17 |
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
XEN1101, Placebo - Focal Onset Seizures | Phase 3 | Completed | 380 | 2022-11-18 | 2026-05-14 |
Metformin Efficacy and Safety in Epileptic Patients
Levetiracetam &/or sodium valproate, Metformin - Epilepsy | Phase 3 | Completed | 60 | 2022-10-18 | 2024-12-02 |
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
Vatiquinone - Inherited Mitochondrial Disease | Phase 3 | Completed | 101 | 2022-06-22 | 2025-12-22 |
Helicobacter Pylori Eradication Therapy for Epileptic Children
Triple therapy for H. pylori infection - Epilepsy, Generalized, Helicobacter Pylori Infection | Phase 2 / Phase 3 | Completed | 126 | 2022-04-20 | 2024-01-29 |
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Completed | 84 | 2022-03-30 | 2025-10-22 |
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Xcopri - Partial Epilepsy | Phase 3 | Completed | 154 | 2022-01-10 | 2026-10-16 |
A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome
Placebo, Soticlestat - Lennox Gastaut Syndrome (LGS) | Phase 3 | Completed | 270 | 2021-11-08 | 2026-09-10 |
A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome
Soticlestat, Placebo - Dravet Syndrome (DS) | Phase 3 | Completed | 144 | 2021-10-28 | 2026-09-04 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Brivaracetam, Placebo - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Completed | 154 | 2021-07-29 | 2026-10-30 |
Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy
Brivaracetam - Epilepsy, Focal | Phase 3 | Completed | 141 | 2021-02-07 | 2026-05-04 |
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment
Lacosamide - Epilepsy | Phase 3 | Completed | 48 | 2020-12-28 | 2025-08-28 |
Randomized Therapy In Status Epilepticus
Ganaxolone, Placebo - Status Epilepticus | Phase 3 | Completed | 100 | 2020-12-09 | 2025-05-29 |
Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
Fenfluramine Hydrochloride - Photosensitive Epilepsy | Phase 3 | Completed | 20 | 2019-05-31 | 2024-11-06 |
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
Atogepant - Episodic Migraine | Phase 3 | Completed | 685 | 2019-05-06 | 2022-05-12 |
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
ZX008 (Fenfluramine Hydrochloride) - Dravet Syndrome, Lennox Gastaut Syndrome | Phase 3 | Completed | 412 | 2019-04-22 | 2025-11-17 |
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Brivaracetam - Partial Seizures With or Without Secondary Generalization, Epilepsy | Phase 3 | Completed | 10 | 2019-01-04 | 2021-04-13 |
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
Atogepant, Placebo - Episodic Migraine | Phase 3 | Completed | 910 | 2018-12-14 | 2021-07-09 |
Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
ganaxolone, Placebo - CDKL5 Deficiency Disorder | Phase 3 | Completed | 101 | 2018-06-30 | 2023-04-14 |
Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint
BRV vs LEV in randomized double blinded, crossover fashion - Photosensitive Epilepsy | Phase 2 / Phase 3 | Completed | 16 | 2018-06-01 | 2019-03-26 |
Showing 20 of 229. Sign in to see all of them.
Narrower conditions
Seizures (84) · Epilepsies, Partial (52) · Lennox Gastaut Syndrome (14) · Epilepsies, Myoclonic (10) · Epilepsy, Complex Partial (9) · Epilepsy, Generalized (9) · Epilepsy, Tonic-Clonic (6) · Drug Resistant Epilepsy (5) · Epilepsy, Idiopathic Generalized (5) · Migraine Disorders (5) · Spasms, Infantile (5) · Brain Diseases (4) · Epilepsy, Absence (3) · Mental Disorders (3)
Broader conditions
Central Nervous System Diseases (229) · Nervous System Diseases (229) · Brain Diseases (225) · Pathological Conditions, Signs and Symptoms (93) · Signs and Symptoms (92) · Neurologic Manifestations (89) · Epileptic Syndromes (33) · Epilepsy, Generalized (26) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Genetic Diseases, Inborn (17) · Headache Disorders (6) · Headache Disorders, Primary (6) · Pathologic Processes (6) · Disease Attributes (4)
Interventions
Levetiracetam (32) · Lacosamide (23) · brivaracetam (20) · Topiramate (15) · Pregabalin (13) · eslicarbazepine acetate (11) · Lamotrigine (10) · Cannabidiol (8) · Fenfluramine (6) · Zonisamide (6) · 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)- (5) · Carbamazepine (5) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (5) · Oxcarbazepine (4) · Valproic Acid (4)
Sponsors
UCB Pharma (28) · GlaxoSmithKline (15) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (12) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (11) · UCB BIOSCIENCES, Inc. (11) · UCB Pharma SA (11) · Eisai Inc. (10) · UCB Japan Co. Ltd. (10) · Bial - Portela C S.A. (8) · Pfizer (7) · SK Life Science, Inc. (7) · Jazz Pharmaceuticals (6) · UCB Biopharma SRL (5) · Lady Hardinge Medical College (4) · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (4)
Countries
United States (111) · France (65) · Poland (64) · Germany (61) · Spain (53) · Italy (50) · Russia (47) · Belgium (44) · Canada (43) · Australia (41) · Hungary (41) · Japan (39) · United Kingdom (37) · Czechia (35) · Mexico (34)
Top investigators
Satinder Aneja, MD (4) · Eric H Kossoff, MD (2) · Hiroki Takano (2) · Janet K Johnson, PhD (2) · Joel Trugman, MD (2) · A. James Fessler, MD (1)
Results publications
PMID 26899665, PMID 33825230, PMID 34218211, PMID 33461041, PMID 35285519, PMID 27265725, PMID 27335114, PMID 27589414, PMID 27608437, PMID 27988967, PMID 28004320, PMID 28236727, PMID 28279891, PMID 29414542, PMID 29908435, PMID 32432339, PMID 33338829, PMID 34155568, PMID 34768178, PMID 34870321, PMID 35582748, PMID 38788664, PMID 17283312, PMID 19327967, PMID 19863578, PMID 21095488, PMID 22512894, PMID 26471380, PMID 26666500, PMID 27683846, PMID 29363050, PMID 33142014, PMID 33179247, PMID 33540241, PMID 33780735, PMID 33797076, PMID 33942560, PMID 34033237, PMID 34246118, PMID 34265088, PMID 34265173, PMID 36435010, PMID 37052803, PMID 38462625, PMID 39648629, PMID 40775196, PMID 10227614, PMID 10371538, PMID 10768306, PMID 10768307
NIH funding
2014 (18), 2004 (6), 2008 (4), 2015 (3), 2016 (3), 2009 (2), 2017 (1), 2018 (1), 2019 (1), 2023 (1), R01NS040808 (1), R01NS054805 (1), U01NS045803 (1)